David Bernstein, M.D. Joins PAION As Medical Advisor & Non Executive Director Of PAION Inc

MAHWAH, N.J., May 7, 2015 /PRNewswire/ -- PAION, Inc., a wholly owned subsidiary of PAION AG, is pleased to announce today that David Bernstein, M.D. has agreed to become PAION's Medical Advisor. In this role, Dr. Bernstein will participate in building the company's U.S. relationships with the academic community, regulators, associations and industry. He will also play an active role in the growth of the company's value proposition, with a special focus on the U.S.

Dr. Bernstein will also be heavily involved in steering PAION's efforts with its recently established medical advisory board, which consists of U.S. national thought leaders in the field of gastroenterology who are also participating in our phase 3 program.

Dr Wolfgang Sohngen, M.D., Ph.D., chief executive officer of PAION AG, said, "I'm thrilled to continue to work with Dr. Bernstein to bring Remimazolam to a commercial success. David's contributions in helping us put together our medical advisory board last year were significant. We hope this will be a long and rewarding relationship with one of the most respected physicians in the field of gastroenterology."

Greg Papaz, president and chief executive officer of PAION, Inc., added: "It is a privilege to have a physician of David's prestige as a director of PAION Inc. I am confident he will help us achieve our goals in the U.S."

Dr. Bernstein is currently chief of hepatology for both North Shore University Hospital and Long Island Jewish Hospital, as well as the director of the Center for Liver Diseases for the North Shore LIJ Health System and a professor of medicine at the Hofstra North Shore LIJ School of Medicine. Dr. Bernstein has authored over 100 publications, 10 book chapters, and has been the principle investigator in more than 100 clinical trials. His work has been published in such prestigious journals as the New England Journal of Medicine and The Lancet.

Dr. Bernstein has held elective offices in many national and international societies. He is the current president of the Bockus International Society of Gastroenterology and a former president of the New York Gastrointestinal Association. He served for six years as the American College of Gastroenterology governor for Long Island and was a member of numerous other medical committees. Currently, he is a fellow of the American Association for the Study of Liver Diseases, the American College of Gastroenterology and the American College of Physicians. He also serves as a special consultant to the New York State Department of Health. He has received numerous awards recognizing his contributions, in academia, as a clinician, and in the field of public health.

"I am delighted to be involved with Remimazolam, a welcome alternative for which gastroenterologists have waited many years. I look forward to the challenges ahead and I am confident that we will see the potential of Remimazolam fully realized in the United States," commented Dr. Bernstein.

PAION will be present at the Digestive Disease week (DDW 2015) between May 17-19, 2015 in Washington, U.S. and will be available for discussions at booth 1865 in the exhibition hall.

About Remimazolam
Remimazolam is an innovative ultra-short-acting general sedative/anesthetic. As a result of its short duration of action and good controllability, it has a preferable efficacy and safety profile relative to other currently marketed anesthesia compounds. Remimazolam's rapid offset is a consequence of its metabolism by tissue esterase enzymes that are widely distributed throughout the body. Remimazolam has potential in three indications:

Procedural sedation (Lead indication U.S.)
General anesthesia (Lead indication EU, Japan)
ICU sedation (Phase 2 Japan)
Remimazolam is available for licensing outside China, Russia (CIS) Turkey, MENA Region, South Korea and Canada, where the compound is partnered with Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm and Pendopharm.

About PAION
PAION AG is a publicly-listed Specialty Pharma Company headquartered in Aachen, Germany with further sites in Cambridge, UK and New Jersey, US. The company has a track record of developing hospital-based treatments for which there is substantial unmet medical need. PAION's strategy is to participate in the commercialization of Remimazolam and extend its business with a focus on anesthesia/critical care products. Remimazolam is the building block for its future marketing activities.

For more information please visit www.paion.com

PAION Corporate Contact
Greg Papaz
President and CEO
PAION, Inc.
201-512-8850
[email protected]

Media Contact
Matt Middleman, M.D.
Russo Partners
(212) 845-4272
[email protected]

PAION AG Contact
Ralf Penner
Director Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen Germany
Phone: +49 241 4453-152
E-mail: [email protected]
www.paion.com

Investor Relations Support in the US
The Trout Group
Thomas Hoffman
+1 646 378 2931 Direct
[email protected]
www.troutgroup.com

Disclaimer:

This release contains certain forward-looking statements concerning the future business of PAION, Inc. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION, Inc's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION, Inc. has no obligation to periodically update any such forward-looking statements to reflect future events or developments.

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.